

August 26, 2011

To whom it may concern:

Company Name : TOHO HOLDINGS CO., LTD.  
Representative : Norio Hamada /  
President and Representative Director  
(Securities Code: 8129 / First Section of Tokyo Stock Exchange)  
Contact : Katsuya Kato, Corporate Officer and  
General Manager of Corporate Communications Office  
and Corporate Planning Office  
(TEL: 03-5259-9520)

### Notice Regarding the Acquisition of Shares by a Subsidiary

As announced in the Notice Regarding the Commencement of Consultations for the Establishment of a Business Alliance between Toho Pharmaceutical Co., Ltd. and Koizumi Yakuhin Co., Ltd., released on March 10 this year, TOHO HOLDINGS CO., LTD. (hereinafter “TOHO HOLDINGS”) and IWAKI & CO., LTD. (hereinafter “IWAKI”) have promoted concrete consultations concerning a business alliance with regard to a reagent business. TOHO HOLDINGS is pleased to announce that, as a result of the above consultations, both companies have concluded today an agreement on the transfer of stock and, consequently, TOHO PHARMACEUTICAL CO., LTD., (hereinafter “TOHO PHARMACEUTICAL”), a consolidated subsidiary of TOHO HOLDINGS will acquire all the outstanding shares of Koizumi Yakuhin Co., Ltd. (hereinafter “Koizumi Yakuhin”), a consolidated subsidiary of IWAKI as of October 1, 2011 (effective date).

#### 1. Reason for the Stock transfer

TOHO PHARMACEUTICAL is engaged in the sales of prescription pharmaceuticals, reagents and medical devices throughout the 47 prefectures of Japan as a pharmaceutical wholesaling company of the Kyoso Mirai Group, with TOHO HOLDINGS as its core company.

On the other hand, Koizumi Yakuhin was originally founded as Koizumi Pharmacy in April 1892. Since April 1966, the Company has been deploying aggressive sales activities as a wholesaling company for reagents as part of the IWAKI Group in Tohoku district, mainly in Miyagi prefecture.

Recently, both TOHO HOLDINGS and IWAKI did specific discussions for a business tie-up between TOHO PHARMACEUTICAL and Koizumi Yakuhin under the common understanding that it is essential to respond to customer needs through the improvement of specialization in various pharmaceutical business fields and enhancement of the functions of medical delivery systems by utilizing management resources of both companies for the wholesaling business of clinical reagents in Tohoku district.

## 2. Outlines of the Parties

### • IWAKI & CO., LTD. (Securities Code: 8095 / First Section of Tokyo Stock Exchange)

Business contents	Sales of pharmaceuticals, raw materials for medicines and cosmetics, chemicals, food products, and so forth.
Establishment	September 20, 1941
Principal place of business	4-8-2, Nihonbashi Honcho, Chuo Ward, Tokyo
Corporate representative	Osamu Iwaki / President and CEO
Capital	2.572 billion Yen
Net sales	50,412 million yen (Consolidated financial year ended November 31, 2010)

### • Koizumi Yakuhin Co., Ltd. (Subsidiary of IWAKI)

Business contents	Sales of in vitro diagnostic reagents, medical equipment and pharmaceutical products.
Establishment	November 30, 1948
Principal place of business	3-4-7, Oroshi-machi, Wakabayashi Ward, Sendai City, Miyagi
Corporate representative	Masahiko Kato / President
Capital	24 million yen
Net sales	1,548 million yen (Financial year ended November 31, 2010)

### • TOHO HOLDINGS CO., LTD. (Securities Code: 8129 / First Section of Tokyo Stock Exchange)

Business contents	Holding company's function, namely control and management of operating companies
Establishment	September 17, 1948
Principal place of business	5-2-1 Daizawa, Setagaya Ward, Tokyo
Corporate representative	Norio Hamada / President and Representative Director
Capital	10,649 million yen
Net sales	1,059,612 million yen (Consolidated financial year ended March 31, 2011)

### • TOHO PHARMACEUTICAL CO., LTD. (Subsidiary of TOHO HOLDINGS)

Business contents	Wholesales of pharmaceuticals, over-the-counter (OTC) pharmaceuticals, reagents, medical equipment and others.
Establishment	November 4, 2008
Principal place of business	5-2-1 Daizawa, Setagaya Ward, Tokyo
Corporate representative	Hiroyuki Kono / President and Representative Director
Capital	300 million yen
Net sales	1,005,498 million yen (Financial year ended March 31, 2011)

## 3. Schedule

August 26, 2011	Conclusion of agreement on the stock transfer
October 1, 2011	Stock transfer date (effective date)

## 4. Impact on business performance

Impact on future the company's consolidated operating results are considered insignificant.